Short answer: A compounded topical finasteride–minoxidil preparation combines a 5-alpha-reductase inhibitor (finasteride) with a follicle-growth stimulator (minoxidil) in one prescription-only topical liquid, serum or cream for androgenetic alopecia. Randomised trials and systematic reviews report that the combination produces greater improvements in hair density and target-area hair count than minoxidil alone, while the topical route limits — but does not eliminate — the systemic finasteride exposure associated with the oral tablet. In Malaysia, a compounded combination preparation is prepared only on a registered doctor’s prescription under Good Compounding Practice (GCP), for one named patient.
Why prescribe a compounded finasteride–minoxidil combination?
Androgenetic alopecia in both men and women is driven by the progressive miniaturisation of genetically susceptible scalp follicles under the influence of dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha-reductase. The two most established pharmacological actives address different parts of this mechanism.
Minoxidil, applied topically, is thought to prolong the anagen (growth) phase of the hair cycle and increase follicle size, though its precise mechanism remains incompletely understood. Finasteride inhibits type II 5-alpha-reductase, reducing the conversion of testosterone to DHT at the follicle. Bringing both actives together in one topical preparation targets both pathways simultaneously.
A systematic review and meta-analysis of finasteride combined with topical minoxidil for androgenetic alopecia concluded that the combination therapy produced significantly greater improvements in hair count and hair density compared with minoxidil monotherapy, with a tolerability profile that was broadly comparable in the studies reviewed (Chen et al., Aesthetic Plastic Surgery, 2020; PMID 32166351). The review’s authors noted that the evidence base, while consistent, is drawn from a limited number of controlled trials with heterogeneous formulations — a limitation prescribers should weigh when evaluating the expected magnitude of benefit.
What the clinical evidence shows
Combination therapy trials
A prospective, randomised, controlled, assessor-blinded, three-arm pilot trial compared the association of topical minoxidil and topical finasteride against each agent used alone in men with androgenetic alopecia. The combination arm demonstrated superior improvements in hair density metrics compared with either monotherapy, supporting the rationale for prescribing both actives together (Rossi et al., Journal of Cosmetic Dermatology, 2024; PMID 37798906).
A 2025 randomised controlled trial evaluated the efficacy and safety of a combination therapy of topical 0.1% finasteride with 5% minoxidil in male androgenetic alopecia. The study reported that the combination produced statistically significant improvements in hair growth parameters compared with baseline, with a favourable safety profile over the study period (Lubis et al., Archives of Dermatological Research, 2025; PMID 40208341).
An earlier randomised, double-blind controlled study compared a topical solution of 0.25% finasteride admixed with 3% minoxidil against 3% minoxidil solution alone in men with androgenetic alopecia. The finasteride–minoxidil combination demonstrated significantly greater improvements in hair count and hair density at the end of the treatment period, with no significant difference in adverse-event rates between the two groups (Suchonwanit et al., Journal of the European Academy of Dermatology and Venereology, 2018; PMID 29972712).
A 2024 comparative study of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in male pattern androgenic alopecia similarly found that the combination outperformed minoxidil monotherapy on key hair-growth endpoints (Asad et al., Journal of Drugs in Dermatology, 2024; PMID 39496123).
Topical finasteride as the foundation of the combination
The finasteride component of the combination rests on its own evidence base. A phase III, randomised, controlled clinical trial of a topical finasteride spray solution in male androgenetic alopecia reported a statistically significant improvement in target-area hair count versus vehicle control, with adverse-event rates broadly comparable to the vehicle group (Piraccini et al., Journal of the European Academy of Dermatology and Venereology, 2022; PMID 34634163).
A systematic review of topical finasteride in androgenetic alopecia covering both male and female patients concluded that topical formulations show efficacy in improving hair growth parameters, with a lower incidence of sexual side effects than oral finasteride in the studies reviewed (Lee et al., Journal of Drugs in Dermatology, 2018; PMID 29601622). The review’s authors cautioned that the evidence base is heterogeneous in formulation and study design — a limitation that remains relevant for the combination as well.
A more recent systematic review of androgenic alopecia management broadly confirms that topical finasteride, including in combination with minoxidil, holds a place among the pharmacological options available to prescribers (Rosenthal et al., Journal of Cosmetic and Laser Therapy, 2024; PMID 38852607).
Systemic exposure: what the prescriber needs to know
The principal rationale for choosing a topical finasteride formulation — whether alone or in combination — is to concentrate the 5-alpha-reductase inhibition at the scalp while reducing the systemic exposure that accompanies the oral 1 mg tablet. However, topical finasteride is still absorbed percutaneously to some degree, and measurable reductions in serum DHT have been reported in clinical studies. The topical route is not a way to eliminate systemic risk entirely; it is a way to reduce it, and the magnitude of that reduction depends on the concentration, vehicle and application area. Prescribers should discuss this with patients who have concerns about systemic finasteride exposure and should monitor accordingly.
Practical considerations for Malaysian clinics
Prescription and referral pathway
In Malaysia, a compounded topical finasteride–minoxidil preparation is classified as a prescription-only compounded medicine. The process begins with a registered doctor’s prescription specifying the exact concentrations of each active, the vehicle (topical liquid, serum or cream), the application instructions and the quantity. The compounding pharmacy then prepares the formulation under the Ministry of Health’s Good Compounding Practice (GCP) guideline, for one named patient. There is no direct-purchase route, and no preparation is supplied without a valid prescription.
What a prescriber can specify
A compounding request for a finasteride–minoxidil combination typically defines:
- Finasteride concentration: Commonly 0.1% to 0.25%, though a prescriber may specify a different strength based on the patient’s profile.
- Minoxidil concentration: Typically 3% to 5%, or higher where the prescriber judges it appropriate.
- Vehicle: A topical liquid (applied via dropper or spray), a serum, or a cream — chosen based on scalp condition, patient preference and the solubility profile of the actives.
- Excipient adjustments: A preparation can be made without a specific excipient — for example, without propylene glycol for patients with known sensitivity — where the vehicle chemistry permits.
Comparison: combination topical vs. separate products
| Feature | Compounded combination (one preparation) | Separate minoxidil solution + oral finasteride |
|---|---|---|
| Number of products | One topical preparation | Two products (topical + oral tablet) |
| Application | Once or twice daily to scalp | Topical to scalp + oral tablet daily |
| Systemic finasteride exposure | Reduced (topical absorption only) | Full systemic exposure (oral) |
| Strength customisation | Both actives at prescriber-specified concentrations | Fixed commercial strengths only |
| Adherence | Single application | Two separate regimens |
| Excipient control | Vehicle and excipients selectable | Fixed commercial vehicle |
What to expect: treatment timeline and patient counselling
Prescribers should set realistic expectations. Visible improvement from topical finasteride–minoxidil therapy typically requires 6 to 9 months of consistent use, with initial assessment at 3 to 4 months. An initial shedding phase in the first 6 to 8 weeks is common with minoxidil-containing preparations and is not a sign of treatment failure. Treatment is long-term: discontinuation generally reverses gains within 6 to 12 months.
Patients should be counselled that the preparation is for external scalp application only, that it should be kept away from children and pets, and that any adverse effects — local irritation, itching, or systemic symptoms — should be reported to their prescribing doctor promptly.
Discussing a compounded finasteride–minoxidil preparation with Lynnity
Lynnity Pharma prepares compounded topical finasteride–minoxidil preparations as a topical liquid, serum or cream, on a registered doctor’s prescription under Good Compounding Practice (GCP). The prescriber specifies the exact concentrations of each active, the vehicle and any excipient adjustments; the pharmacy prepares to that specification for one named patient. For clinics in Kuala Lumpur and the Klang Valley that manage androgenetic alopecia, this route allows a combination therapy that no single commercial product offers, at strengths the prescriber chooses. Lynnity also prepares compounded minoxidil as a standalone topical in various vehicles, and compounded finasteride as a standalone topical — each on prescription, each individualised to the patient. All compounded preparations are prepared at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.
To discuss a patient-specific finasteride–minoxidil combination preparation, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.
Frequently asked questions
Is compounded topical finasteride–minoxidil available in Malaysia?
Yes — as a prescription-only compounded preparation prepared by a licensed compounding pharmacy under GCP. It is not a registered, mass-manufactured product and cannot be bought directly. A registered doctor’s prescription is required.
What strengths of finasteride and minoxidil are used in the combination?
Finasteride is commonly prescribed at 0.1% to 0.25%, and minoxidil at 3% to 5%, in a compounded topical preparation. The prescriber sets the exact concentrations based on the patient’s clinical profile.
Does topical finasteride cause the same side effects as oral finasteride?
Systematic reviews report a lower incidence of sexual side effects with topical finasteride compared with oral finasteride in the studies reviewed. However, topical finasteride is still absorbed to some degree, and measurable reductions in serum DHT have been reported. It does not eliminate systemic risk.
How long does it take to see results from a compounded finasteride–minoxidil topical?
Visible improvement typically requires 6 to 9 months of consistent use. An initial shedding phase in the first 6 to 8 weeks is common and does not indicate treatment failure. Treatment is long-term; stopping generally reverses gains within 6 to 12 months.
Can a patient use a compounded finasteride–minoxidil preparation alongside other hair-loss treatments?
This depends on the specific combination and should be evaluated by the prescribing doctor. The prescriber can incorporate additional compatible actives into the compounded formulation or advise on concurrent therapies. Polypharmacy decisions remain with the clinician.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).